NeurAxis (NASDAQ:NRXS) and Cytosorbents (NASDAQ:CTSO) Critical Review

NeurAxis (NASDAQ:NRXS – Get Free Report) and Cytosorbents (NASDAQ:CTSO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for NeurAxis and Cytosorbents, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis 0 1 1 0 2.50
Cytosorbents 1 0 2 0 2.33

NeurAxis currently has a consensus target price of $13.00, suggesting a potential upside of 154.10%. Cytosorbents has a consensus target price of $104.75, suggesting a potential upside of 2,093.72%. Given Cytosorbents’ higher possible upside, analysts clearly believe Cytosorbents is more favorable than NeurAxis.

Valuation & Earnings

This table compares NeurAxis and Cytosorbents”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NeurAxis $6.53 million 8.34 -$14.63 million ($1.06) -4.83
Cytosorbents $37.06 million 0.41 -$8.20 million ($5.80) -0.82

Cytosorbents has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NeurAxis has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Institutional and Insider Ownership

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 7.8% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NeurAxis and Cytosorbents’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeurAxis -492.76% N/A -641.25%
Cytosorbents -45.06% -689.23% -41.26%

Summary

Cytosorbents beats NeurAxis on 9 of the 14 factors compared between the two stocks.

About NeurAxis

(Get Free Report)

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.

About Cytosorbents

(Get Free Report)

Cytosorbents Corp. develops blood-purification technologies for use in hospitals and other clinical settings. Its products are designed to work with extracorporeal circuits, where blood is circulated outside the body and passed through a purification device. The company’s best-known product, CytoSorb, is an adsorber intended to remove certain inflammatory substances and other compounds from blood. It is used in areas such as critical care and cardiac surgery. Cytosorbents also develops DrugSorb-ATR, a device designed to remove certain blood-thinning drugs during cardiac procedures.

Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.